Feed/Companies/SRTD Biotech

SRTD Biotech

As of 9 Nov 2026, SRTD Biotech has raised $35.2M across 1 verified round on record (amounts in other currencies converted to USD), plus 1 round still being checked; latest: €31.5M seed round led by Boehringer Ingelheim Venture Fund, Mérieux Equity Partners and 1 other, announced 9 Nov 2026.

BUILT ON

A biotech company focused on developing new precision mRNA therapeutics

srtd-biotech.comLinkedInJülich, GermanyBiotechFounded 2019

LATEST ROUND

Seed

$35.2M · 2026-11-09

RAISED ON RECORD · USD

$35.2M

across 1 verified round · plus 1 round still being checked

INVESTORS

4 leads

SOURCES

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 2 ]

Seed

$35.2M · 2026-11-09

led by Boehringer Ingelheim Venture Fund, Mérieux Equity Partners, NRW.BANK

Seedseed financing round

n/a · 2024-11-14

[ HISTORY ]

led by High-Tech Gründerfonds (HTGF)

Round	Amount	Announced	Lead	Buzz
Seed	$35.2M €31.5M	2026-11-09	Boehringer Ingelheim Venture Fund, Mérieux Equity Partners, NRW.BANK	3 outlets. #8 in Trending
7 sources [ VERIFIED ] read against 4 of 7 sources Sources agree on the seed round, amount, date, investors, and headquarters.

Company research

Fetched today

SRTD Biotech develops precision RNA/mRNA therapeutics that switch on only in diseased cells, aiming to treat cancer, autoimmune disease, fibrosis and other conditions with high unmet medical need.

Founders

Dr. Bernd Hoffmann · Chief Scientific Officer and Founder
Dr. Heribert Bohlen · Founder

WHY IT MATTERS

SRTD’s seRNA platform combines intracellular disease-RNA markers with fusogenic lipid nanoparticles to express therapeutic payloads in diseased cells while minimizing exposure in healthy tissue, addressing a central limitation of non-selective mRNA therapies. The company says its €31.5 million seed financing will fund preclinical targeted-RNA programs in oncology, autoimmune disease and fibrosis toward IND, making the round a significant bet on translating this platform into clinical candidates.

Checked against 10 sources today

SOURCES

srtd-biotech.com//news

SRTD Biotech

Company

Rounds

Sources

Profile

Investors

SRTD Biotech

Rounds

Company research

Sources

Seed$35.2M2026-11-097 sources

Seed2024-11-142 sources

Investors

Seed$35.2M2026-11-096 investors

Seed2024-11-141 investor

Seed seed financing round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	n/a	2024-11-14	High-Tech Gründerfonds (HTGF)	No recent discussion
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources Lead added High-Tech Gründerfonds (HTGF) · htgf.de The release gives no exact amount or currency. It mentions unnamed business angels but does not identify them.; not on the page it cites, so not applied: amount [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: htgf.de, finsmes.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent